Is your team confident in handling the complicated logistics that come with cell and gene trials?
November 06, 2020
Nothing is standard about the study design, study conduct or the regulatory process in cell and gene therapy trials. Every cell and gene therapy is different due to the specific characteristics of each product, with a complicated regulatory approval process and unique therapeutic challenges.
Do you have confidence in your trial’s endpoints? Are you pursuing an accelerated pathway or special designation? Will you need to plan for a centralized site model or remote monitoring? Is your team confident in handling the complicated logistics that come with cell and gene trials?
In this webinar, participants will learn an end-to-end approach to bringing a cell and gene therapy to market. You will receive advice from experts responsible for supporting over 100 advanced cell and gene therapy programs. They will share each step of this process covering the planning, execution, submission and post-marketing for trials in the US and EU. The information provided will help participants determine their next step in the development of their cell and gene therapy product.
Join Ewan Campbell, Advanced Therapy & Biotech Director, Veristat; Kevin Hennegan, Senior Regulatory Strategist, Veristat; and Rachel Smith, Project Director, Veristat in a live webinar on Friday, November 20, 2020 at 11am EST (4pm GMT/UK).
For more information, or to register for this event, visit Roadmap to Market for Cell and Gene Therapies.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Share article on social media or email: